MEET OUR

Leadership Team

Magnus Henriks

Chief Executive Officer

Having spent the last decade working in leading business development and corporate management roles, Magnus joined rAAVen Therapeutics as the CEO in April 2024. Prior to this appointment, he also served part time as the CBO for the company, from Oct 2022. 

Magnus has extensive experience in commercial strategy and leadership, having had multiple executive positions in various stock listed and private companies. From mainly working within Scandinavia and the Baltics, the overall objective for Magnus and rAAVen forward will be a global market strategy, where he will oversee all operational and corporate related tasks. 

Marcus Davidsson, PhD

Founder & COO

Prior to founding rAAVen Therapeutics, Marcus spent the last decade on DNA barcoding and AAV engineering. Marcus started his work at Lund University, where he developed novel DNA barcoding methods for AAV engineering and gene therapy. Beside this, he has also 
worked extensively on generating DNA libraries, how to sequence DNA libraries and enhancer-promoter optimization. 
He holds a PhD in Neuroscience from Lund University and has postdoc experience from Michigan State University in Grand Rapids, MI and Barrow Neurological Institute in Phoenix, AZ. 

Patrick Aldrin-Kirk, PhD

Chief Scientific Officer

Patrick joined rAAVen as CSO in 2022 following more than a decade of academic research. He holds a PhD within neurobiology with a focus on the use of engineered AAV vectors, using these to elucidate changes in both disease conditions and during treatment. He was part of the original rAAVen research team that developed the screening platform now in use by rAAVen therapeutics. Patrick continued his scientific career as a postdoc at Copenhagen university, Denmark, which was followed by a position as assistant professor before joining rAAVen Therapeutics.

Yuriy Pomeshchik MD, PhD

Director of In Vitro

Yuriy joined rAAVen Therapeutics in 2024, bringing over 20 years of extensive experience in both in vivo and in vitro research. With a foundational medical education and a PhD in Neurosciences from the University of Eastern Finland, Yuriy has contributed to the development of innovative treatments for spinal cord injuries, focusing on small molecules, stem cells, and gene therapy.  

He advanced his scientific career as a postdoctoral researcher at Lund University in Sweden, where he developed cutting-edge patient stem cell-based models for neurodegenerative diseases. His dedication and expertise led him to an Associate Researcher position, which he held before transitioning to rAAVen Therapeutics.